Extracellular ATP has been shown to either inhibit or promote cancer growth and migration; however, the mechanism underlying this discrepancy remained elusive. Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers. We showed that conditioned media (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human breast cancer MDA-MB-231 cells. Removal of the extracellular ATP by apyrase in CM abolished this effect, suggesting the involvement of ATP. ATP exerted its inhibitory effect through the activation of purinergic P2X receptor signaling in breast cancer cells evidenced by the attenuation of the inhibition by an antagonist, oxidized ATP, as well as knocking down P2X7 with small interfering RNA (siRNA), and the inhibition of migration by an agonist, BzATP. Intriguingly, ATP had a biphasic effect on breast cancer cells-lower dosage inhibited but higher dosage promoted its migration. The stimulatory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ecto-ATPase inhibitor, and A 2A receptor siRNA, suggesting that in contrast to ATP, adenosine, a metabolic product of ATP, promoted migration of breast cancer cells. Consistently, non-hydrolyzable ATP, ATPγS, only inhibited but did not promote cancer cell migration. ATP also had a similar inhibitory effect on the Py8119 mouse mammary carcinoma cells; however, adenosine had no effect owing to the absence of the A 2A receptor. Consistently, ATPγS inhibited, whereas adenosine promoted anchorage-independent growth of MDA-MB-231 cells. Our in vivo xenograft study showed a significant delay of tumor growth with the treatment of ATPγS. Moreover, the extent of bone metastasis in a mouse intratibial model was significantly reduced with the treatment of ATPγS. Together, our results suggest the distinct roles of ATP and adenosine released by osteocytes and the activation of corresponding receptors P2X7 and A 2A signaling on breast cancer cell growth, migration and bone metastasis.
INTRODUCTION
Bone metastases are major, potentially fatal complications associated with advanced cancers, including breast cancer. [1] [2] [3] [4] Bone tissues are the preferred sites of cancer metastasis owing to their microenvironment, which provide a fertile setting in which tumor cells can grow. 5 There are three major cell types in bone tissues: osteocytes, osteoblasts, and osteoclasts. Osteocytes comprise >95% of total bone cells and have an essential role in orchestrating the bone remodeling process by coordinating activities from the osteoclasts and osteoblasts. 6, 7 The roles of osteoblasts and osteoclasts in bone metastasis have been linked to the release of growth factors from the bone matrix, which stimulates tumor growth. 4 However, the role of osteocytes, the most abundant cell type in bone tissue, in bone metastases remains unexplored.
Bisphosphonate drugs are commonly used to treat skeletal complications, such as bone pain, pathological fracture, osteopenia and osteoporosis. This class of drugs is also used to treat bone cancer metastasis and is associated with decreased tumor growth in addition to reduced bone destruction and pain. 8 It has been reported that alendronate (AD), a bisphosphonate drug, induces the opening of hemichannels, a channel permeable to small molecules (Mro 1 kDa) in osteocytes. 9 In addition, osteocytes permit the release of ATP in response to mechanical loading. 10 However, it is unknown whether the ATP molecules, which are released from osteocytes, mediate the inhibitory effect of bisphosphonates on bone metastasis.
Several studies have established the anti-neoplastic activity of extracellular ATP to inhibit the growth of several cancer cell lines, including prostate cancer cells, colon adenocarcinoma cells, melanoma cells and bladder cancer cells. [11] [12] [13] Previous studies point to the possibility that ATP, through its binding to P2 purinergic receptors, exhibits an anti-cancer effect. 12 The activation of purinergic signaling is also reported to inhibit proliferation and migration of human acute myeloblastic leukemia cells in immune-deficient mice. 14 Additionally, in vivo studies show that daily injections of ATP significantly inhibit tumor growth, prolong survival time and inhibit weight loss in mice. 15 However, the effect of adenosine nucleotides on cancer bone metastasis is largely unexplored. Our study demonstrates that ATP released from bone osteocytes exerts inhibitory effects on breast cancer cells. ATPγS, a non-hydrolyzable analogue of ATP, has a similar inhibitory effect on breast cancer cell migration. In contrast to the effect by ATP, adenosine, a metabolic product, promoted human breast cancer cell migration, and this stimulatory effect was attenuated with an adenosine receptor antagonist. Moreover, we showed the inhibitory effect by ATP and the stimulatory effect by adenosine were primarily mediated by the activation of P2X7 and A 2A receptors, respectively. These results suggest that adenosine nucleotides released from osteocytes and their activating signaling mechanisms have significant impacts on the migration and growth of tumor cells and cancer metastasis to the bone.
RESULTS
ATP released by AD-treated osteocytes inhibits the migration of human breast cancer cells To determine the underlying mechanism of the bisphosphonates in suppressing cancer metastasis to the bone, we treated osteocytic MLO-Y4 cells with AD and collected the CM. The result from the transwell cell migration assay showed that CM collected from the MLO-Y4 osteocytes treated with AD significantly decreased the migration of MDA-MB-231 cells (127 ± 12 cells to 38 ± 12 cells) ( Figure 1a ). To eliminate the possibility of any effects from proliferation, the WST-1 cell proliferation assay was performed by incubating the MDA-MB-231 breast cancer cells in the identical CM and time duration as used in the transwell migration assay. The proliferation of the MDA-MB-231 cells incubated in CM from MLO-Y4 cells treated with 20 μM AD (CM-AD) was similar to that of the MDA-MB-231 cells incubated in untreated CM (CM) (Figure 1b ). To determine whether ATP released from osteocytes would have an effect on MDA-MB-231 cell migration, we depleted ATP from the CM collected from MLO-Y4 cells using apyrase, an ATP hydrolyzing enzyme. The addition of apyrase increased MDA-MB-231 cell migration by 2.5-fold in untreated CM and 7.7-fold in CM-AD ( Figure 1a ). To exclude the possibility that AD might have direct effects on MDA-MB-231 cells, we performed the transwell cell migration assay with the MDA-MB-231 cells with AD added directly to the CM collected from MLO-Y4 cells. The results showed that there was no difference in migration when incubated with AD ( Figure 1c ). These results suggest that ATP released from osteocytes upon AD treatment can inhibit the migration of human breast cancer cells.
To test the effect of purinergic signaling activated by ATP on breast cancer cell migration, we treated the CM with oxidized ATP, a potent inhibitor of P2X purinergic receptors. The addition of oxidized ATP significantly attenuated the inhibitory effect of CM-AD on MDA-MB-231 cell migration (Figure 2a ). Consistently, the addition of BzATP, a non-hydrolyzable P2X7 receptor agonist, caused a significant, dose-dependent decrease in breast cancer migration (0 μM = 110 ± 11.6 cells, 10 μM = 99 ± 7.8 cells, 100 μM = 64 ± 4.4 cells, 200 μM = 39 ± 2.6) ( Figure 2b ). The result from the WST-1 assay showed that the treatment with BzATP at concentrations 1-200 μM had minimal effects on cell proliferation, and a significant reduction was only observed at 400 μM (Supplementary Figure S1 ). These data support an inhibitory role Figure 1 . ATP released by osteocytes treated with AD has inhibitory effect on migration of human breast cancer cells. (a) Depletion of ATP by apyrase from CM collected from AD-treated osteocytes increases breast cancer cell migration. CM was collected from MLO-Y4 cells treated with (CM-AD) or without (CM) 20 μM AD for 48 h and was then treated with or without apyrase (5 units/ml), an ATP hydrolyzing enzyme for 4 h before being used to culture MDA-MB-231 cells in transwells. The cells migrated through the transwell filter were stained with Hema 3 Stat Pack (Fisher Scientific; upper panel). The numbers of the cells migrated were quantified. Data were presented as mean ± s.e.m. n = 3. *Po 0.05; ***P o0.001. (b) CM collected from AD-treated MLO-Y4 cells has no effect on human breast cancer cell proliferation. MDA-MB-231 breast cancer cells were incubated for 18 h in CM collected from MLO-Y4 cells with (CM-AD) or without (CM) 20 μM AD for 48 h. Cell proliferation was analyzed by WST-1 assay. Data are presented as mean ± s.e.m. n = 3. (c) AD has no effect on human breast cancer cell migration. CM was collected from MLO-Y4 cells without (CM) AD for 48 h. Before incubation with MDA-MB-231 breast cancer cells for 18 h, 20 μM AD was directly added to the CM. Data are presented as mean ± s.e.m. n = 3. for P2X receptor activation in the migration of human breast cancer cells.
ATP inhibits but adenosine promotes the migration of breast cancer cells
To determine the direct involvement of ATP, we applied ATP into the CM. Surprisingly, the treatment of 200 μM ATP did not decrease but increased the migration of MDA-MD-231 cells in both CM collected from AD and non-AD-treated MLO-Y4 cells (153 ± 21.1 vs 88 ± 10.7 and 188 ± 33.5 vs 127 ± 2, respectively) ( Figure 3a ). To further test the effect of ATP, we treated MDA-MB-231 cells with ATP at varying concentrations ( Figure 3b ). We found that the inhibitory effect of ATP was only observed at lower concentration (0 μM = 150 ± 4.8 cells vs 50 μM = 100 ± 17.7 cells) but higher concentration instead promoted Figure S2 ). This increase in migration is possibly due to higher levels of adenosine formed as a product of the increased break down of ATP at higher concentrations, as extracellular ATP is known to be readily hydrolyzed to adenosine by a group of enzymes known as ectonucleotidases. 16 To test for the possible effects of adenosine as a result of ATP hydrolysis, a potent adenosine receptor antagonist, MRS1754 was used. As a selective adenosine receptor antagonist, MRS1754 specifically inhibits A 2B receptors at low concentrations, but at higher concentrations, MRS1754 is known to inhibit other P1 receptors (A 1 and A 2A ). The addition of high concentration (500 nM) of MRS1754 attenuated the stimulatory effect of ATP on the migration (Figure 3a ). Moreover, MRS1754 further augmented the inhibitory effect of CM-AD on cell migration, suggesting these adverse effects were mediated by adenosine. To verify the effects of MRS1754 by itself on MDA-MB-231 cell migration and to reveal the specific P1 receptor(s) involved, we treated the media directly with a low concentration (2 nM) and a high concentration (500 nM) of MRS1754 (Supplementary Figure S3A ). There was no significant difference in migration with the low concentrations (A 2B receptors blocked), but at high concentrations (A 1 , A 2A and A 2B receptors blocked), the migration was reduced by >2.6-fold (Supplementary Figure S3A ). The cell viability was not affected by the different concentrations of MRS1754 (Supplementary Figure S3B ). As a further confirmation, we applied an ecto-ATPase inhibitor, ARL67156, which prevents the breakdown of ATP. The addition of ARL67156 attenuated the stimulatory effect of higher dosage of ATP on the migration of the breast cancer cells ( Figure 3c ). The addition of ARL67156 to media also triggered a decrease in migration (Supplementary Figure S4A ). However, the effect of ARL67156 on cell migration was not caused by changes in cell proliferation (Supplementary Figure S4B) . To demonstrate the effect of ATP in the absence of its break down, we used a non-hydrolyzable ATP analogue, ATPγS, which is a broad agonist of P2 receptors. The application of this reagent to control CM significantly reduced the migration of MDA-MB-231 cells (from 112 ± 2.4 cells to 63 ± 9.6 cells) ( Figure 3d ). The significant reduction of cancer cell migration by ATPγS was further demonstrated in a dose-dependent manner (0 μM = 69 ± 3.8 cells, 50 μM = 46 ± 9.3 cells, 100 μM = 33 ± 3.3 cells, 200 μM = 11 ± 1.7, 400 μM = 9 ± 1.5 cells) ( Figure 3e ). These data confirm the inhibitory role of ATP on breast cancer cell migration and imply the opposite role of adenosine.
We further tested the effect of adenosine on MDA-MB-231 cell migration. CM collected from MLO-Y4 cells were treated with or without adenosine. MRS1754 was also added to verify the specific effect from adenosine. The treatment of adenosine increased MDA-MB-231 cell migration, whereas this increase was completely attenuated with the addition of 500 nM MRS1754 ( Figure 4a ). The enhanced cell migration by adenosine was not a result of increased cell proliferation as the treatment of adenosine at various concentrations had minimal effects on cell proliferation (Supplementary Figure S5 ). These data indicated the possible involvement of A 1 and A 2A receptors. To further determine whether a similar effect was also observed with the hydrolysis of ATP, we added apyrase to the CM. Consistently, the increase of migration as a result of apyrase treatment was significantly attenuated by MRS1754 ( Figure 4b ). To ascertain the specific P1 receptor subtype that is stimulated by adenosine to enhance breast cancer cell migration, we utilized a selective A 2A receptor antagonist, ANR94. The viability of MDA-MB-231 cells is unaffected by ANR94 up to concentrations of 100 μM; therefore, we used this concentration in future experiments (Supplementary Figure S6 ). The blocking of A 2A receptors by ANR94 dramatically decreased the migration of MDA-MB-231 cells (Figure 4c ). Based on these data, we concluded that adenosine has a stimulatory role on breast cancer cell migration, and this effect is likely mediated through the adenosine A 2A receptor. These results further suggest the divergent roles of ATP and adenosine on breast cancer cell migration: the inhibitory role by ATP and the stimulatory role by adenosine.
The levels of ATP and adenosine in the CM (MLO-Y4 cells treated with AD for 48 h) were measured by liquid chromatography-mass spectrometry (LC-MS). In all, 10 or 20 μM AD increase the ATP by 102.1 ± 17.85-or 221.6 ± 18.45-fold compared with the control CM, respectively. Adenosine levels were also increased in the CM from MLO-Y4 cells treated with 20 μM AD, to a lesser degree compared with ATP levels (4.8 ± 0.1-fold compared with control CM). This data further support the notion that ATP released by osteocytes treated with AD is responsible for the inhibitory effect on the breast cancer cells. On the other hand, the lesser increase of adenosine possibly due to the hydrolysis of ATP in CM-AD failed to exert a predominant effect on promoting breast cancer cells.
P2X7 mediates the migration-inhibiting effects from ATPγS, whereas A 2A mediates the migration-promoting effects from adenosine in MDA-MB-231 cells We investigated the specific involvement of P2X7 in the ATP-induced inhibition of migration as well as A 2A receptors in adenosine-induced increase of migration by silencing the expression of P2X7 and A 2A using small interfering RNA (siRNA). We confirmed that mRNA expression of P2X7 and A 2A receptors were decreased by transfection with P2X7 and A 2A siRNA, respectively (Figure 5a ). In P2X7 knocked down cells, ATPγS failed to induce a decrease in migration, whereas a dramatic decrease is seen with control siRNA-transfected cells (Figure 5b ). Additionally, adenosine failed to promote migration in A 2A knocked down cells, whereas control cells transfected with control siRNA exhibited significant increase in migration ( Figure 5c ). These results indicate the specific involvement of P2X7 and A 2A receptors in ATP and adenosinemediated migration effects, respectively.
ATPγS inhibits but adenosine promotes anchorage-independent growth of human breast cancer cells
To determine whether ATP and adenosine have similar effects on the anchorage-independent growth of human cancer cells, we cultured MDA-MB-231 breast cancer cells in soft agar ( Figure 6 ). Similar to their effects on the cell migration, ATPγS significantly inhibited colony formation of MDA-MB-231 cells (from 82 ± 4.5 colonies to 47 ± 6.2 colonies), whereas adenosine had an opposite effect by significantly promoting colony formation (132 ± 13.7 colonies). These results suggest that ATP and adenosine not only affect cell migration but also have a major impact on human breast cancer cell growth.
ATP and ATPγS inhibited the migration of mouse mammary carcinoma cells
We tested adenosine nucleotides on Py8119, a mouse mammary carcinoma cell line, as this cell is capable of metastasizing to other tissues in immunocompetent wild-type mice and has been used in an in vivo metastatic model. 17 ATP at varying concentrations was added to the CM collected from MLO-Y4 cells treated with (CM-AD) or without (CM) 20 μM AD. The transwell cell migration assay was conducted with Py8119 cells incubated in these CM. With the increase of dosage, the migration of the Py8119 cancer cells decreased, with the most significant effect at 400 μM (from 254 ± 25.9 cells to 159 ± 7.8 cells with CM and from 127 ± .3 cells to 88 ± 10.3 cells for CM-AD) ( Figure 7a ). The migration of Py8119 cells was also decreased with the treatment of ATPγS (Figure 7b ). These results suggest that similar to MDA-MB-231 breast cancer cells, ATP has an inhibitory role on Py8119 mouse mammary carcinoma cells and further implies a broad role of ATP on breast cancer bone metastasis. We then tested whether adenosine has a similar stimulatory effect on the Py8119 cells as it had on the MDA-MB-231 cells. The transwell migration assay was conducted with Py8119 cells incubated in media containing various concentrations of adenosine ( Figure 7c ). We found that the migration of Py8119 cells was not changed, regardless of the concentration of adenosine added. Furthermore, Py8119 cell migration was unaffected by either low or high concentrations of MRS1754 (Supplementary Figure S3C ). Blocking the specific A 2A receptors with ANR94 treatment did not affect migration patterns either (Figure 7d ). This indicates that, unlike the human breast cancer cell line MDA-MB-231, the migration of the mouse mammary carcinoma cell line Py8119 is not sensitive to adenosine.
The insensitivity of Py8119 cells to adenosine could be caused by the absence of certain adenosine receptors. To investigate the specific purinergic receptor subtypes that are expressed on MDA-MB-231 and Py8119 cells, we examined the mRNA expression of all P1 and several P2 receptors. We chose P2X5, P2X7, P2Y1, P2Y2 and P2Y11, as these are the P2 receptor subtypes most implicated in cancer. 11, 12 MDA-MB-231 cells express all P1 receptors but A 3 , as well as all five P2 receptors assessed (Supplementary Figure S7) . Py8119 cells express all P1 receptors except A 2A , as well as P2X5, P2X7 and P2Y2. Receptor P2Y11 was not evaluated in Py8119 cells as there has not been a rodent ortholog of P2Y11 reported. 18 These results suggest that the different response of Py8119 cells to adenosine stimulation could be due to its lack of the A 2A receptor as this receptor subtype, as shown above, is responsible for the effect of adenosine on MDA-MB-231 cells.
ATPγS inhibited the tumor growth of human mammary carcinoma cells in nude mouse xenografts
Our in vitro data demonstrated the inhibitory effect of ATP on breast cancer cell growth and migration. To test whehter ATP has a similar, inhibitory effect on tumor growth in vivo, we used an orthotopic mouse model. MDA-MB-231 cells were orthotopically implanted into the mammary fat pads of athymic female nude mice. After the mice were randomly assigned into three different treatment groups, the mice were treated with or without ATPγS or adenosine. Dosages were determined by a previous study showing no toxicity from intraperitoneal injections of up to 50 mM of adenine nucleotides into mice for 10 days. 15 At the end of the study, the tumors were excised and weighed. We found that the mice treated with ATPγS exhibited significantly reduced tumor growth rate in comparison to the control group, whereas the adenosine-treated mice had an increase in tumor growth rate (Figure 8a ). The reduced mean tumor volume of the treatment group was statistically significant after 17 days of ATPγS treatment. In postmortem analysis, the tumors excised from the mammary fat pads showed significantly (>four-fold) decreased sizes in the ATPγS-treated group as compared with the control group. Additionally, the adenosine-treated group had 50% increased tumor sizes compared with the control group tumors (Figure 8b) . These results reveal that systemic administration of ATPγS had an inhibitory effect on the growth of human breast cancer cells in vivo.
ATPγS inhibited the tumor growth and metastasis of mouse mammary carcinoma cells in vivo
To assess how systemic treatment with ATPγS may affect the growth of breast cancer cells in the bone microenvironment of a syngeneic host, we performed intratibial injections in wild-type C57bl/6 female mice using the mouse mammary carcinoma cell line Py8119. The mammary tumor cells were injected into the right tibias of the female mice, and the tumor growth was monitored with whole-body imaging once a week for 4 weeks.
Bioluminescence analysis of the animals revealed that treatment with ATPγS significantly inhibited tumor growth in the tibias (Figure 9 ). Our results indicate that mice injected with ATPγS had a dramatic reduction in tumor burden after 4 weeks of treatment as reflected by bioluminescence signals from the images taken in both the dorsal (right panels) and ventral (left panels) positions. Quantification data (lower panels) further confirmed the significant decrease of tumor growth in the bone with the treatment of ATPγS.
DISCUSSION
The growth and migration of tumor cells are largely influenced by their microenvironment, and bone is one of the most preferred sites for cancer metastasis. 4 Osteocytes, the most abundant bone cell type, are known to release several factors, including prostaglandin, nitric oxide and ATP, by mechanical stimulation. 19 Although osteocytes comprise >95% of total cells in the bone, their involvement in cancer bone metastasis is unknown. We observed that CM collected from AD-treated osteocytes decreased the numbers of breast cancer cells migrating to the other side of the transwell membrane. This decrease is caused by a reduction of cell migration but not a reduction of cell viability, as the WST-1 assay failed to detect any alteration in the cell number. Furthermore, direct treatment with AD did not result in any change, indicating that the decrease in cell migration was not due to direct effects from AD. The inhibitory effect is likely to be mediated by ATP as depletion of ATP by apyrase or application of an antagonist of P2X receptors completely attenuated such effects. Additionally, the use of a P2X7 agonist inhibited the migration, while ATPγS added to cells transfected with P2X7 siRNA had no effect. We would expect that direct treatment with ATP could inhibit the migration. However, we observed a biphasic effect of ATP on the migration of MDA-MB-231 breast cancer cells: low concentration inhibited, but high concentrations promoted. Extracellular ATP can be hydrolyzed by ectonucleotidases released from the cell. 16 We suspected that products of ATP hydrolysis, such as adenosine, might exert an inverse effect from ATP on cancer cell migration. Indeed, prevention of ATP hydrolysis by an ecto-ATPase inhibitor, ARL67156, averted the stimulation of higher dosage of ATP on breast cancer cell migration. Moreover, treatment with non-hydrolyzable ATP analogues, ATPγS or BzATP, significantly attenuated this adverse effect. Additionally, ATPγS reduced MDA-MB-231 cell growth assessed by the soft agar colony-formation assay. Consistently, we showed that adenosine has an opposite effect from ATP in promoting the growth and migration of human breast cancer cells. The treatment of an adenosine receptor antagonist or A 2A siRNA attenuated the stimulatory effect of adenosine on cancer cells. Therefore, we have to be cautious when investigating the involvement of ATP on tumorigenesis or other diseases as it could largely depend on the stability of this molecule in the body.
Extracellular nucleotides and nucleosides have been shown to participate in signal transduction through purinergic receptors and affect a variety of cellular functions and processes, such as inflammation, development and regeneration, and cancer. 20 Several previous studies have shown the increased levels of adenosine nucleotides in the tumor microenvironment. Adenosine concentrations increase under metabolically unfavorable conditions, such as cancer. Studies have demonstrated higher levels of extracellular adenosine in a solid tumor microenvironment compared with normal tissue (about two-fold increase). 21 The physiological ATP concentration in human blood is normally submicromolar (20-100 nM), and it is estimated that the pericellular ATP concentration is in the low nanomolar range. Based on one study, tumor cells generate a microenvironment in which the ATP concentration is in the 100-μM range. 22 We quantified the ATP and adenosine in our CM and discovered over a 100-fold increase in ATP levels into the media from osteocyte release after AD treatment. The increased adenosine level was much less dramatic, although it was several fold in difference compared with untreated osteocytes. The levels of ATP and adenosine released from the osteocytes into the CM are comparable to what is found in the aforementioned studies. This suggests that adenosine nucleotides may have a role in bone metastasis.
The main pathway leading to high adenosine levels is the hydrolysis of ATP by ectonucleotidases, such as CD39 and CD73. CD73 catalyzes the conversion of AMP to adenosine and has been associated with a pro-metastatic phenotype in breast cancer. CD73 is overexpressed in ER-negative breast cancer cell lines and clinical samples. 23 Its expression is upregulated in both primary tumors and lymph node metastases. Additionally, knocking down CD73 in MDA-MB-231 breast cancer cells leads to growth suppression and inhibition of invasion and migration both in vivo and in vitro. 24 Furthermore, CD73 promotes the migration and invasion of both T47D and MDA-MB-231 breast cancer cells as confirmed with the use of overexpression and inhibition, revealing that adenosine increases the mobility of T47D and MDA-MB-231 cells. 25 As an enzyme that produces adenosine, CD73 is able to tightly regulate adenosine receptor interaction in many tissues. Therefore, it is important to not exclude the possibility that the stimulatory effects that we observe in breast cancer cell migration and invasion may be partly due to the ectonucleotidase control of adenosine signaling.
Previous literature reported conflicting observations with regard to the roles of ATP and purinergic receptors in tumorigenesis. In accordance with our study, published studies have indicated biphasic effects of ATP on cancer cells. Multiple studies indicated that the action of ATP on P2 purinergic receptors leads to an anticancer effect. 12 On the other hand, other studies have shown that activation of P2 receptors in some breast cancer cell lines could cause an increase in cell migration and invasion. 26 This discrepancy could possibly be due to varying expression levels of P2 ATP receptors reported among different breast cancer cells types or activation of P1 adenosine receptors due to the ATP hydrolyzation by endonucleases. Additionally, there is increased expression of certain P2X receptors in breast tissue undergoing malignant change compared with normal breast tissue. 12 Consistent with our observation of human breast cancer cells, a similar stimulatory effect of adenosine on cancer cell chemotaxis has been observed previously for A2058 melanoma cells, and this response was inhibited by adenosine receptor antagonists. 27 Bladder and prostate carcinomas seem to be inhibited by the activation of the P1 adenosine receptors, and anti-proliferative, pro-apoptotic and pro-necrotic effects have been reported in several other different cell types. 11, 13 It has also been reported that human primary breast tumor tissues express higher levels of P1 adenosine receptors than in matched normal breast tissues. 28 However, none of the published reports uncovered the biphasic effects of ATP as a result of its degradation and the adverse effect of adenosine in the same cancer cells. We found that the treatment with adenosine promoted human breast cancer cell migration. To further determine the specific roles of P2X7 and A 2A receptors in influencing breast cancer cell migration, we used an RNAi method to knock down the expression of P2X7 or A 2A with siRNA transfection. We found that the downregulation of P2X7 in MDA-MB-231 cells resulted in no effect when a P2 receptor agonist, ATPγS, was added. Furthermore, downregulation of A 2A lead to no effect when a P1 receptor agonist, adenosine, was added. These data indicate the specific roles of P2X7 and A 2A receptors in the inhibition and promotion of MDA-MB-231 cell migration, respectively.
We sought further confirmation of the role of ATP/adenosine in breast cancer cells by using an additional mammary carcinoma cell line from mouse, Py8119. Intriguingly, in contrast to the observation in MDA-MB-231 cells, Py8119 cell migration was inhibited by ATP, even at high concentrations. Through further investigation, we found that this discrepancy is due to the insensitivity of Py8119 cell migration to adenosine. MDA-MB-231 migration was inhibited by P1 receptor antagonists, such as MRS1754 (blocks A 1 , A 2A and A 2B ) and ANR94 (blocks A 2A ), whereas Py8119 cell migration was unaffected by treatment with either pharmacological antagonist. Consistent with this, assessment of the purinergic receptor mRNA expression in both MDA-MB-231 and Py8119 cells revealed that Py8119 cells lack A 2A expression, suggesting a possible reason for the lack of response to adenosine. These results suggest that A 2A receptors could be the major purinergic receptor subtype involved in mediating the effect of adenosine in promoting breast cancer migration. Further investigation is warranted to determine the involvement of this receptor in other breast cancer cells as well as during cancer progression and metastasis.
We used two in vivo models to demonstrate the differential effects of adenosine nucleotides on breast cancer growth and bone metastasis. First, we applied a breast cancer xenograft model where MDA-MB-231 human breast cancer cells were orthotopically injected into the mammary fat pad of nude female mice. This method is often used to examine primary tumor growth. 29 We chose this model to study the influence of adenosine nucleotides on breast cancer cell growth. Consistent with our in vitro observation of the anchorage-independent cell growth assay, human breast cancer cell growth was significantly attenuated with the treatment of ATPγS, whereas adenosine inversely enhanced the tumor growth in situ. The intracardiac metastasis model is often used to study the metastatic behavior of cancer cells into different organs. 30 However, because of the difficulty of producing bone metastases using the intracardiac injection metastasis model with breast cancer cells, we opted for the intratibial injection method. Intratibial injections are often performed for the purpose of studying the relationship of cancer cells and bone after a tumor has already metastasized to bone. 29 We directly injected tumor cells into the bone marrow cavity of the tibia to study the effects of ATPγS on the growth of mammary tumor cells in a bone microenvironment. Our in vivo studies demonstrate that systemic administration of the non-hydrolyzable ATPγS had an inhibitory Clinically, intravenous ATP has been safely trialed in patients with advanced lung cancer. 31 In another randomized controlled trial, ATP infusions in patients with advanced non-small cell lung cancer had significantly increase overall survival at 9.3 months for ATP-treated vs 3.5 months for control-treated patients. 32 There was a particularly significant survival benefit in the subgroup of patients with stage IIIB non-small cell lung adenocarcinoma, as opposed to stage IV, suggesting that the treatment is more effective at earlier stages. In another study, ATP treatment in 99 preterminal cancer patients (life expectancy o 6 months) increased the short-term (0-8 weeks) and long-term (0-6 months) survival. 33 Although the exact mechanism of the patient response remains unclear, it is evident that ATP has considerable effect on survival. Together, our results point to the differential roles of adenosine nucleotides and purinergic receptors in breast cancer invasion and metastasis and imply the possibility of utilizing these purinergic receptors as potential targets in cancer metastasis therapeutics.
MATERIALS AND METHODS Materials
MLO-Y4 osteocytic cells derived from mouse long bones were kindly provided by Lynda Bonewald (University of Missouri at Kansas City). AD (4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid), ATP, ATPγS (adenosine 5′-[γ-thio] triphosphate tetralithium salt), BzATP (2′(3′)-O-(4benzoylbenzoyl)adenosine-5′-triphosphate tri(triethylammonium) salt), oxidized ATP, adenosine, apyrase and MRS1754 were purchased from Sigma-Aldrich (St Louis, MO, USA). ARL67156 was purchased from R&D Systems (Minneapolis, MN, USA).
Cell lines and cell cultures
The human breast carcinoma cell line MDA-MB-231 cells were grown in McCoy's 5A Modified Media (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA). The murine mammary carcinoma cell line Py8119 cells were grown in F12K nutrient media (Gibco) supplemented with 5% Fetal Clone II (Fisher Scientific, Hampton, NH, USA). MLO-Y4 cells were cultured on rat tail collagen type I (BD Biosciences, San Jose, CA, USA) coated cell culture plates. Cells were cultured in α-modified essential medium supplemented with 2.5% fetal bovine serum and 2.5% bovine calf serum (Hyclone). All cell lines were incubated in a 5% CO 2 incubator at 37°C.
CM preparation
MLO-Y4 cells were seeded onto 150-mm dishes (Corning, Corning, NY, USA) and incubated for 24 h to allow attachment, after which media was removed and changed with α-modified essential medium without phenol red (Gibco) supplemented with 2.5% fetal bovine serum and 2.5% bovine calf serum (Hyclone). MLO-Y4 cells were incubated in the absence or presence of 20 μM AD in a 5% CO 2 incubator at 37°C for 48 h, and the CM was collected.
Cell proliferation assay
Cell proliferation was assessed using the WST-1 (Water Soluble Tetrazolium salts) assay (Roche, Basel, Switzerland). A single-cell suspension was plated in 96-well plates at 2.0 × 10 4 cells/well and allowed to attach to the plates at 37°C for 2 h. The cells were then treated with CM collected from MLO-Y4 cells treated with or without 20 μM AD for 18 h. After the treatment, cell viability was measured by adding 10 μl of Cell Proliferation Reagent WST-1 to each well and incubated for 1 h at 37°C in a 5% CO 2 incubator. The cell proliferation was measured at an emission wavelength of 450 nm with a Synergy HT Multi-Mode Microplate Reader (Biotek, Winooski, VT, USA). 
Cell migration assay
Migration assays were performed in transwell membrane filter inserts in 24-well tissue culture plates (BD Biosciences). The transwell membrane filter inserts contained 6.5-mm diameter, 8-μm pore size, 10-nm thick polycarbonate membranes. The breast cancer cell lines were harvested and resuspended in CM from MLO-Y4 cells with or without other compounds. Five-hundred microliter breast cancer cell suspensions were added to the upper side of the inserts at a density of 10 × 10 4 cells/insert, and 750 μl CM with or without other compounds was added to the lower wells. Cells were incubated at 37°C for 18-20 h. Cells that did not migrate through the filters were removed using cotton swabs, and cells that migrated through the inserts were fixed and stained with Hema 3 Stat Pack (Fisher Scientific). The number of migrated cells in five fields of view per insert was counted under a light microscope Olympus (Tokyo, Japan) at magnification × 10. 
Reverse transcriptase-PCR
Total RNA was extracted from MDA-MB-231 and Py8119 cells using the GeneJet RNA Purification kit (Thermo Scientific). cDNA was synthesized by incubating 11 μl RNA (50 ng/μl) with 1 μl Random Primers (Promega, Fitchburg, WI, USA) at 70°C for 10 min, transferred to ice for 3 min and then was incubated with 4 μl of 5X First Buffer (Invitrogen, Carlsbad, CA, USA), 1 μl of 10 mM dNTP mix and 2 μl of 0.1 M DTT (Promega, Fitchburg, WI, USA). The reaction mix was incubated at 42°C for 5 min and then was incubated with 1 μl Superscript Reverse Transcriptase (Invitrogen) at 42°C for 1 h. The reaction was terminated by incubating at 70°C for 15 min and then with 1 μl RNase H (Thermo Scientific) at 37°C for 20 min. Primer pairs for PCR were designed and verified by basic local alignment search tool (BLAST) to detect specific P1 and P2 receptors ( Table 1) . Optimal annealing temperatures for each primer pair was determined by testing PCR with genomic DNA using annealing temperatures ranging from 55 to 64°C. PCR was performed using JumpStart Taq DNA polymerase (Sigma-Aldrich), and PCR products were separated on 2% agarose gels. Negative controls comprised of no template (water) to monitor for PCR product contamination. Genomic DNA was used as the positive control.
Soft agar colony-formation assay
For anchorage-independent cell growth, MDA-MB-231 cells were plated in 0.4% agarose with complete medium supplemented with either 100 μM ATPγS or 200 μM adenosine on top of a 0.8% agarose base supplemented with complete medium. Cells were maintained for about 2 weeks before staining with p-iodonitrotetrazolium violet (Sigma-Aldrich). The pictures were taken by a scanner, and the numbers of colonies were counted.
Quantification of ATP and adenosine using LC-MS
ATP and adenosine were measured from the CM directly after filtering through a 5000 NMWL Ultrafree-MC filter unit (Millipore, Bedford, MA, USA) containing adenosine-13C10, 15N5-triplosphate (ATP13C, 15N) as internal standard, modified from Zhang et al. 34 LC-MS analysis was conducted on a Thermo Fisher Q Exactive mass spectrometer with on-line separation using a Thermo Fisher/Dionex Ultimate 3000 HPLC. HPLC conditions were: Waters XTerra-MS C18 column (3.5 μm, 150 mm × 2.1 mm i.d.); mobile phase A, 5 mM Hexylamine and 0.5% diethylamine in water, pH10; mobile phase B, 50% acetonitrile in water; flow rate, 400 μl/min; and gradient, 1% B to 20% B over 10 min and followed by 20% B to 30% B over 10 min. Fullscan mass spectra were acquired in the orbitrap using negative ion detection over a range of m/z 300-800 at 70 000 resolution (m/z 300). Identification was based on the metabolite accurate mass (±5 p.p.m.) and in agreement with the HPLC retention time of authentic standards. Quantification was made by integration of extracted ion chromatograms of ATP and adenosine followed by comparison with the corresponding standard curves.
Animals
Four-week-old female athymic nude mice (Harlan Sprague-Dawley, Indianapolis, IN, USA) were used for the mammary fat pad injections. Four-to-five-week-old female C57bl/6 mice were used for the intratibial injections. Animals were maintained under the care and supervision of the Laboratory Animal Research facility at the University of Texas Health Science Center, San Antonio, TX, USA. The animal protocol was approved and monitored by the Institutional Animal Care and Use Committee.
In vivo xenograft experiment MDA-MB-231 cells were injected subcutaneously in the mammary fat pad of 4-week-old female nu/nu athymic nude mice. Each mouse received bilateral subcutaneous inoculation in both the left and right inguinal mammary fat pad areas with 100 μl of cell suspension containing 1 × 10 7 cells/ml in serum-free media. Animals were randomly assigned to three different groups, and solid tumors were allowed to form up to about 5 mm 3 volume before treatments began. ATPγS, at 400 μM/500 μl saline, adenosine, at 400 μM/500 μl saline, or 500 μl of saline, were administered intraperitoneally three times a week for 3 weeks. The growth of xenograft tumors was monitored twice a week, and tumor size was measured with a caliper in two dimensions. Tumor volumes were calculated with the equation V = (LxW 2 ) × 0.5 (mm 3 ), where L is the length and W is the width of a tumor.
Intratibial injections
Mice were anesthetized by isoflurane and were also given buprenorpine-HCl (0.3 mg/ml) as an analgesic. Intratibial injections were performed as described previously. 35 Py8119 cells expressing Luc-GFP (1 × 10 5 in 20 μl of phosphate-buffered saline) were inoculated into the bone marrow area of right tibias through the hole made previously by a Hamilton syringe fitted with a 30-gauge needle. Phosphate-buffered saline was injected into the left tibias as control. ATPγS, at 400 μM/500 μl saline or 500 μl of saline, was administered intraperitoneally twice a week for 5 weeks, beginning from day 1. Intratibial tumor growth was monitored with bioluminescence imaging with a Xenogen IVIS-Spectrum imaging system (Xenogen, Alameda, CA, USA) every week starting from 3 days after tumor cell inoculation.
Bioluminescence imaging analysis
Mice were anesthetized and D-luciferin (Caliper Life Sciences, Alameda, CA, USA) was injected intraperitoneally at 75 mg/kg in phosphate-buffered saline. Xenogen IVIS Spectrum Imaging system (Xenogen) was used to acquire bioluminescence images at 10 min after injection. Acquisition time was set at 60 s at the beginning and reduced later on in accordance with signal strength to avoid saturation. Analysis was performed using the LivingImage software (Xenogen) by measurement of photon flux (measured in photons/sec/cm 2 /steradian) with a region of interest drawn around the bioluminescence signal to be measured. Tumor burden was taken by drawing an region of interest around the major bioluminescence signal from the hind limb.
Statistical analysis
Unless otherwise specified in the figure legends, the data are presented as the mean ± s.e.m. of at least three determinations. Asterisks indicate the degree of significant differences compared with the controls (*Po0.05; **Po0.01; ***Po 0.001). One-way analysis of variance and the Student-Newman-Keuls test were used to compare groups using the GraphPad Prism 5.04 software (GraphPad, La Jolla, CA, USA).
